Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | June 14, 2018 | June 15, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date June 14, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.14 · Expires 2028-06-14 | Direct | 12,500 |
Reported balance
After 2018-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-14 · Grant · Acquired 12,500 · Balance 12,500 F1: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Flexion Therapeutics Inc
Report date November 19, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Disposition to issuer · Disposed 335,498 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: Includes 517 shares of Issuer common stock acquired under the Issuer's 2013 Employee Stock Purchase Plan on November 17, 2021. F3: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. |
| Common StockSEC Table I · non-derivative | IndirectBy the Michael D.Clayman 2006 Revocable Trust | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 373,769 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. |
| Common StockSEC Table I · non-derivative | IndirectBy the Michael D. Clayman Irrevocable Trust | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 24,600 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Development Fund III, LLC | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 388,683 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F4: Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.52 · Expires 2023-07-18 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-19 · Disposition to issuer · Disposed 136,530 · Balance 0 F5: At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) any potential CVR Payments, net of any withholding taxes required to be deducted and withheld by applicable legal requirements. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.61 · Expires 2024-03-02 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-19 · Disposition to issuer · Disposed 200,000 · Balance 0 F6: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.91 · Expires 2025-01-20 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-11-19 · Disposition to issuer · Disposed 110,000 · Balance 0 F6: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.20 · Expires 2026-01-03 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-11-19 · Disposition to issuer · Disposed 155,000 · Balance 0 F6: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.56 · Expires 2026-12-19 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-11-19 · Disposition to issuer · Disposed 175,000 · Balance 0 F6: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.31 · Expires 2028-01-31 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-11-19 · Disposition to issuer · Disposed 116,667 · Balance 0 F6: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.75 · Expires 2029-02-28 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-11-19 · Disposition to issuer · Disposed 290,000 · Balance 0 F6: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.78 · Expires 2030-03-01 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-11-19 · Disposition to issuer · Disposed 185,000 · Balance 0 F6: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Performance Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-11-19 · Disposition to issuer · Disposed 106,100 · Balance 0 F7: At the effective time of the Merger, each outstanding restricted stock unit award conditioned on performance metrics ("PSU") was accelerated (assuming achievement at 100% of the applicable target levels) and became fully vested and cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such PSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.
F2: Includes 517 shares of Issuer common stock acquired under the Issuer's 2013 Employee Stock Purchase Plan on November 17, 2021.
F3: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
F4: Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.
F5: At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) any potential CVR Payments, net of any withholding taxes required to be deducted and withheld by applicable legal requirements.
F6: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
F7: At the effective time of the Merger, each outstanding restricted stock unit award conditioned on performance metrics ("PSU") was accelerated (assuming achievement at 100% of the applicable target levels) and became fully vested and cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such PSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 19, 2021 Filed Nov 19, 2021 09:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerPerformance Restricted Stock Unit Award · Derivative | 106,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-065703 · doc4.xml · derivative · entry 13 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,100 shares Expires not disclosed F7 · derivative.exercise_price: At the effective time of the Merger, each outstanding restricted stock unit award conditioned on performance metrics ("PSU") was accelerated (assuming achievement at 100% of the applicable target levels) and became fully vested and cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such PSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. F7 · price: At the effective time of the Merger, each outstanding restricted stock unit award conditioned on performance metrics ("PSU") was accelerated (assuming achievement at 100% of the applicable target levels) and became fully vested and cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such PSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. F7 · derivative.exercise_date: At the effective time of the Merger, each outstanding restricted stock unit award conditioned on performance metrics ("PSU") was accelerated (assuming achievement at 100% of the applicable target levels) and became fully vested and cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such PSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. F7 · derivative.expiration_date: At the effective time of the Merger, each outstanding restricted stock unit award conditioned on performance metrics ("PSU") was accelerated (assuming achievement at 100% of the applicable target levels) and became fully vested and cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such PSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 09:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 185,000 | Not disclosed Strike: $15.78 | Not disclosed |
DisclosureSEC source: 0001209191-21-065703 · doc4.xml · derivative · entry 12 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 185,000 shares Expires 2030-03-01 F6 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F6 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 09:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 290,000 | Not disclosed Strike: $14.75 | Not disclosed |
DisclosureSEC source: 0001209191-21-065703 · doc4.xml · derivative · entry 11 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 290,000 shares Expires 2029-02-28 F6 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F6 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 09:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 116,667 | Not disclosed Strike: $22.31 | Not disclosed |
DisclosureSEC source: 0001209191-21-065703 · doc4.xml · derivative · entry 10 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 116,667 shares Expires 2028-01-31 F6 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F6 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 09:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 175,000 | Not disclosed Strike: $18.56 | Not disclosed |
DisclosureSEC source: 0001209191-21-065703 · doc4.xml · derivative · entry 9 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 175,000 shares Expires 2026-12-19 F6 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F6 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 09:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 155,000 | Not disclosed Strike: $18.20 | Not disclosed |
DisclosureSEC source: 0001209191-21-065703 · doc4.xml · derivative · entry 8 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 155,000 shares Expires 2026-01-03 F6 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F6 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 09:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 110,000 | Not disclosed Strike: $22.91 | Not disclosed |
DisclosureSEC source: 0001209191-21-065703 · doc4.xml · derivative · entry 7 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,000 shares Expires 2025-01-20 F6 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F6 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 09:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 200,000 | Not disclosed Strike: $17.61 | Not disclosed |
DisclosureSEC source: 0001209191-21-065703 · doc4.xml · derivative · entry 6 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2024-03-02 F6 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F6 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 09:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock Option (right to buy) · Derivative | 136,530 | Not disclosed Strike: $2.52 | Not disclosed |
DisclosureSEC source: 0001209191-21-065703 · doc4.xml · derivative · entry 5 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 136,530 shares Expires 2023-07-18 F5 · price: At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) any potential CVR Payments, net of any withholding taxes required to be deducted and withheld by applicable legal requirements. F5 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) any potential CVR Payments, net of any withholding taxes required to be deducted and withheld by applicable legal requirements. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 09:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerCommon Stock | 388,683 | $8.50 | $3,303,805.50 |
DisclosureSEC source: 0001209191-21-065703 · doc4.xml · nonDerivative · entry 4 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Versant Development Fund III, LLC Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F4 · ownership.nature: Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 09:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerCommon Stock | 24,600 | $8.50 | $209,100.00 |
DisclosureSEC source: 0001209191-21-065703 · doc4.xml · nonDerivative · entry 3 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael D. Clayman Irrevocable Trust Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 09:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerCommon Stock | 373,769 | $8.50 | $3,177,036.50 |
DisclosureSEC source: 0001209191-21-065703 · doc4.xml · nonDerivative · entry 2 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael D.Clayman 2006 Revocable Trust Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 09:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerCommon Stock | 335,498 | $8.50 | $2,851,733.00 |
DisclosureSEC source: 0001209191-21-065703 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2 · shares: Includes 517 shares of Issuer common stock acquired under the Issuer's 2013 Employee Stock Purchase Plan on November 17, 2021. F3 · shares: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 20:44 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Tax withholdingCommon Stock | 13,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-047501 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,981 F1 · kind: Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on July 16, 2020. F1 · price: Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on July 16, 2020. Read SEC document |
| June 21, 2021 Filed Jun 28, 2021 18:04 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 1,700 | $7.78 | $13,226.00 |
DisclosureSEC source: 0001209191-21-043522 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,840 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 1,700 shares by the Reporting Person on June 21, 2021, pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:16 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantPerformance Restricted Stock Unit Award · Derivative | 159,150 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017207 · doc4.xml · derivative · entry 5 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,150 Underlying: Common Stock · 159,150 shares Expires not disclosed F3 · shares: Represents the maximum number of shares deliverable under the performance restricted stock unit award. F4 · derivative.exercise_date: Upon confirmation by the Board of Directors or the Compensation Committee thereof that a specified amount of 2021 revenues from ZILRETTA product sales and certain clinical development milestones are achieved, 25% of the shares eligible for vesting under the restricted stock unit award shall vest in 2022 upon confirmation of such performance metrics being achieved and thereafter on January 1 of the subsequent three years so that all of such shares will have vested on January 1, 2025. F4 · derivative.expiration_date: Upon confirmation by the Board of Directors or the Compensation Committee thereof that a specified amount of 2021 revenues from ZILRETTA product sales and certain clinical development milestones are achieved, 25% of the shares eligible for vesting under the restricted stock unit award shall vest in 2022 upon confirmation of such performance metrics being achieved and thereafter on January 1 of the subsequent three years so that all of such shares will have vested on January 1, 2025. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:16 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 106,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017207 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,001 F1 · shares: Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Read SEC document |
| February 01, 2021 Filed Mar 23, 2021 19:01 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 21,099 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-022677 · doc4.xml · nonDerivative · entry 2 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,140 F2 · kind: On February 1, 2021, the Reporting Person transferred 21,099 shares of the Issuer's Common Stock to The Michael D. Clayman 2006 Revocable Trust. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 20:17 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Tax withholdingCommon Stock | 8,776 | $12.37 | $108,559.12 |
DisclosureSEC source: 0001209191-21-006328 · doc4.xml · nonDerivative · entry 2 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,901 F2 · kind: Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on March 2, 2020. F2 · price: Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on March 2, 2020. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 20:17 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 119,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006328 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,677 F1 · shares: On March 2, 2020, the Reporting Person was granted 175,000 restricted stock units. The vesting of the shares under the restricted stock unit award was to be based on the achievement of a specified amount of 2020 revenues from ZILRETTA product sales established at the time of the Compensation Committee's approval of the restricted stock unit award. On January 27, 2021, the Compensation Committee certified the achievement of a specified amount of 2020 revenues from ZILRETTA product sales resulting in the commencement of vesting of 119,500 shares. The remaining 55,500 restricted stock units granted to the Reporting Person on March 2, 2020, were forfeited based on the above performance metrics. The Reporting Person previously reported the restricted stock units in Table II of Form 4. Read SEC document |
| January 08, 2021 Filed Mar 23, 2021 19:01 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 4,762 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-022677 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,239 F1 · kind: On January 8, 2021, the Reporting Person transferred 4,762 shares of the Issuer's Common Stock to The Michael D.Clayman 2006 Revocable Trust. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 17:47 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Tax withholdingCommon Stock | 2,530 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-002556 · doc4.xml · nonDerivative · entry 2 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,177 F2 · kind: Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on February 1, 2018. F2 · price: Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on February 1, 2018. Read SEC document |
| July 16, 2020 Filed Jul 20, 2020 21:26 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 93,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043111 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,010 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. 1/3 of the shares subject to the restricted stock unit award vest on each of July 16, 2021, July 16, 2022 and July 16, 2023. Read SEC document |
| July 08, 2020 Filed Jan 7, 2021 17:47 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 1,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002556 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,707 F1 · kind: On July 8, 2020, the Reporting Person transferred 1,303 shares of the Issuer's Common Stock to The Michael D.Clayman 2006 Revocable Trust. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 16:18 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 1,303 | $10.83 | $14,111.49 |
DisclosureSEC source: 0001209191-20-038727 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,260 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 1,303 shares by the Reporting Person on June 22, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 26, 2020 Filed May 27, 2020 16:11 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 10,256 | $9.75 | $99,996.00 |
DisclosureSEC source: 0001209191-20-032287 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael D.Clayman 2006 Revocable Trust Disclosed balance after: 346,605 F1 · kind: The shares were purchased in connection with the Issuer's public offering. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 16:10 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantRestricted Stock Unit Award · Derivative | 175,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015098 · doc4.xml · derivative · entry 2 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2024-01-01 F2 · derivative.exercise_date: Upon confirmation by the Board of Directors or the Compensation Committee of the Board that a specified amount of 2020 revenues from ZILRETTA product sales is achieved, 25% of shares subject to the restricted stock unit award shall vest in 2021 upon such confirmation and thereafter on January 1 of the subsequent three years so that all of such shares will have vested on January 1, 2024. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 16:10 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 185,000 | $0.00 Strike: $15.78 | $0.00 |
DisclosureSEC source: 0001209191-20-015098 · doc4.xml · derivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2030-03-01 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares shall vest on the one year anniversary of January 1, 2020 (the "Vesting Commencement Date") and thereafter one-forty-eighth (1/48th) of the total shares shall vest each month following the one year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four (4) years after the Vesting Commencement Date. Read SEC document |
| January 07, 2020 Filed Jan 7, 2020 17:40 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 5,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002305 · doc4.xml · nonDerivative · entry 5 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael D.Clayman 2006 Revocable Trust Disclosed balance after: 336,349 Read SEC document |
| January 07, 2020 Filed Jan 7, 2020 17:40 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 5,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002305 · doc4.xml · nonDerivative · entry 3 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,957 Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 17:40 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Tax withholdingCommon Stock | 2,494 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-002305 · doc4.xml · nonDerivative · entry 2 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,414 F1 · kind: Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on February 1, 2018. F1 · price: Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on February 1, 2018. F2 · balance_after: Includes 659 shares of Common Stock that were acquired by the Reporting Person on December 20, 2019 at $9.89 per share pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 09, 2019 Filed Jan 7, 2020 17:40 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 10,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002305 · doc4.xml · nonDerivative · entry 4 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael D.Clayman 2006 Revocable Trust Disclosed balance after: 330,892 Read SEC document |
| October 09, 2019 Filed Jan 7, 2020 17:40 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 10,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002305 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,249 Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 16:25 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Tax withholdingCommon Stock | 4,402 | $13.98 | $61,539.96 |
DisclosureSEC source: 0001209191-19-052754 · doc4.xml · nonDerivative · entry 2 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,647 Read SEC document |
| October 06, 2019 Filed Oct 8, 2019 16:25 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Exercise / conversionRestricted Stock Unit Award · Derivative | 14,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-052754 · doc4.xml · derivative · entry 6 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,800 shares Expires 2019-10-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: On January 4, 2016, the reporting person was granted up to 66,600 restricted stock units. The amount and vesting of the shares under the restricted stock unit award was based on the achievement of certain milestones that were established at the time of the Compensation Committee's approval of the restricted stock unit award on December 17, 2015. On October 6, 2017, the Compensation Committee certified the achievement of a milestone under the restricted stock unit award resulting in the commencement of vesting of 44,400 shares as follows: 14,800 shares vested as of October 6, 2017, 14,800 shares vested as of October 6, 2018 and 14,800 shares vested as of October 6, 2019. Read SEC document |
| October 06, 2019 Filed Oct 8, 2019 16:25 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Exercise / conversionCommon Stock | 14,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-052754 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 08, 2019 Filed Aug 8, 2019 16:38 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 2,317 | $10.85 | $25,136.21 |
DisclosureSEC source: 0001209191-19-045123 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,249 F1 · price: The weighted average purchase price for the transaction reported was $10.84860, and the range of prices were between $10.83360 and $10.85090. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 24, 2019 Filed Jun 24, 2019 17:23 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 1,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-038817 · doc4.xml · nonDerivative · entry 5 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael D. Clayman 2006 Revocable Trust Disclosed balance after: 320,494 Read SEC document |
| June 24, 2019 Filed Jun 24, 2019 17:23 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 1,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-038817 · doc4.xml · nonDerivative · entry 3 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,932 Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 17:23 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 1,492 | $9.81 | $14,636.52 |
DisclosureSEC source: 0001209191-19-038817 · doc4.xml · nonDerivative · entry 2 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,424 F1 · kind: The shares were acquired by the Reporting Person on June 21, 2019 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 10, 2019 Filed May 13, 2019 09:15 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 4,012 | $12.48 | $50,067.35 |
DisclosureSEC source: 0001209191-19-029182 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,868 F1 · price: The weighted average purchase price for the transaction reported was $12.47940, and the range of prices were between $12.470 and $12.481. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 16:11 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 4,046 | $12.36 | $50,008.56 |
DisclosureSEC source: 0001209191-19-019135 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,856 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:23 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 360,000 | $0.00 Strike: $14.75 | $0.00 |
DisclosureSEC source: 0001209191-19-016478 · doc4.xml · derivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: With respect to 290,000 of the shares subject to the option, 25% of such shares shall vest on the one year anniversary of January 1, 2019 (the "Vesting Commencement Date") and thereafter 1/48th of such shares shall vest each month following the one year anniversary of the Vesting Commencement Date, so that all such shares shall be vested four years after the Vesting Commencement Date. With respect to 70,000 of the shares subject to the option, if the Company's 2019 revenues from ZILRETTA product sales are at least a specified amount, then 17,500 of such shares shall vest on January 1, 2020 and thereafter 1/48th of such shares shall vest each month following January 1, 2020, so that all of such shares shall be vested four years after January 1, 2019. Read SEC document |
| January 28, 2019 Filed Jun 24, 2019 17:23 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 4,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-038817 · doc4.xml · nonDerivative · entry 4 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael D. Clayman 2006 Revocable Trust Disclosed balance after: 319,002 Read SEC document |
| January 28, 2019 Filed Jun 24, 2019 17:23 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 4,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-038817 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,932 Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 17:03 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | SaleCommon Stock | 3,278 | $12.36 | $40,516.08 |
DisclosureSEC source: 0001209191-19-002065 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,810 F1 · shares: Sale of shares of common stock pursuant to Rule 10b5-1 arrangements to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on February 1, 2018. F2 · balance_after: Includes 922 shares of Common Stock that were acquired by the Reporting Person on December 20, 2018 at $10.48 per share pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 09:17 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 5,000 | $17.10 | $85,476.50 |
DisclosureSEC source: 0001209191-18-058086 · doc4.xml · nonDerivative · entry 4 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,166 F1 · price: The weighted average purchase price for the transaction reported was $17.0953, and the range of prices were between $16.95 and $17.33. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| October 11, 2018 Filed Nov 13, 2018 09:17 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 8,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-058086 · doc4.xml · nonDerivative · entry 7 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael D.Clayman 2006 Revocable Trust Disclosed balance after: 314,066 Read SEC document |
| October 11, 2018 Filed Nov 13, 2018 09:17 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 8,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-058086 · doc4.xml · nonDerivative · entry 3 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,166 Read SEC document |
| October 08, 2018 Filed Oct 9, 2018 16:31 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Exercise / conversionRestricted Stock Unit Award · Derivative | 14,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-054525 · doc4.xml · derivative · entry 6 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,800 Underlying: Common Stock · 14,800 shares Expires 2019-10-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: On January 4, 2016, the reporting person was granted up to 66,600 restricted stock units. The amount and vesting of the shares under the restricted stock unit award was based on the achievement of certain milestones that were established at the time of the Compensation Committee's approval of the restricted stock unit award on December 17, 2015. On October 6, 2017, the Compensation Committee certified the achievement of a milestone under the restricted stock unit award resulting in the commencement of vesting of 44,400 shares as follows: 14,800 shares vested as of October 6, 2017, 14,800 shares vested as of October 6, 2018 and 14,800 shares vested as of October 6, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.